Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001310

Drug Information
NameMefloquine    
SynonymsAC1L1HAJ; NCGC00161831-02; WR-142,490; Spectrum4_001066; SPBio_001591; Mefloquina [INN-Spanish]; SPBio_002111; Racemic mefloquine; mefloquine; DivK1c_000790; Prestwick3_000126; Prestwick1_000126; CHEMBL411329; SPECTRUM1503070; Mefloquinum; DB00358; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; WR-177,602; (+)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11S, 2'S)-; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; AC1L9UO6; nchembio.215-comp3; Ro-21-5998-001; NSC157387; 51742-87-1; BRD-A89585551-003-03-4; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Prestwick0_000126; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; CID40692; RTI1172-1-1; BIDD:PXR0166; CHEBI:151162; (+)-(11R,2'S)-erythro-Mefloquine; (+/-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; BPBio1_000190; NCGC00016864-01; C17H16F6N2O; 68682-27-9; AB00052310; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-; Ro 21-5998; C07633; AC1MHD7O; (+)-Threo-Mefloquine; (-)-Threo-Mefloquine; RTI1173-1-1; HSDB 6853; NINDS_000790; HMS502H12; MolPort-003-981-155; RTI1174-1-1; CHEBI:403542; CHEMBL416956; NCGC00161831-01; MQ; Lariam (Hydrochloride); AC1MHD7J; 53230-10-7; (+)-Mefloquine; AC1Q4K1I; HMS1922C09; KBioGR_001392; Mefloquine (USAN/INN); 4-Quinolinemethanol, alpha-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaR)-; RTI1169-1-1; 4-Quinolinemethanol, .alpha.-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.S)-; CID456309; Mefloquinone; RTI1189-1-1; 4-Quinolinemethanol, .alpha.-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.R)-; (+)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 49752-90-1; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-rel-; BIDD:GT0596; Mephloquine; NCGC00094994-02; 51744-84-4; LS-187797; CID3000506; nchembio.87-comp20; Spectrum5_001122; RO 13-7225; RO 13-7224; CID3000516; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; IDI1_000790; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; Lariam; Mefloquinum [INN-Latin]; NCGC00094994-01; KBio2_006928; EINECS 256-468-3; Mefloquin; Spectrum2_001516; 51688-68-7; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; KBio1_000790; RTI1188-1-1; 51744-85-5; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; CAS-51773-92-3; (-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11R, 2'R)-; 4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(.+/-.)-; (+/-)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+/-)-; SPB-80406; AR-1G4597; WR 142490; WR-142490; CHEMBL411685; KBio3_002046; KBioSS_001792; AC1L249S; NCGC00094994-04; Spectrum3_000953; alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; CHEMBL411686; D04895; alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; KBio2_001792; (-)-(11S,2'R)-erythro-Mefloquine; Mefloquine [USAN:INN:BAN]; (-)-Mefloquine; UNII-TML814419R; Prestwick2_000126; Ro 21-5998 (Hydrochloride); Mefloquina; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)-; 4-quinolinemethanol, a-2-piperidinyl-2,8-bis(trifluoromethyl)-; KBio2_004360; CID4046; LS-142023; NCGC00094994-03; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-; BSPBio_000172; Spectrum_001312; Ro 215998    
Trade NameLariam; Mefaquin    
CompanyHoffmann-La Roche pharmaceutical company    
IndicationMalariaApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntimalarials    
CAS NumberCAS 53230-10-7
FormularC17H16F6N2O    
PubChem Compound IDCID 40692.    
PubChem Substance IDSID 181524.    
SuperDrug ATC IDP01BC02;    
SuperDrug CAS ID053230107;    
TargetFood vacuolesBinder[2]
Ref 1The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. To Reference
Ref 2An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543